Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Stacy L. Moulder"'
Autor:
Abenaa M. Brewster, Rashmi Krishna Murthy, Alastair M. Thompson, Nuhad K. Ibrahim, Vicente Valero, Sarah M. DeSnyder, Senthil Damodaran, Helen Piwnica-Worms, Stacy L. Moulder, Gary J. Whitman, Thorunn Helgason, Jennifer K. Litton, Beatriz E. Adrada, Jill Schwartz-Gomez, Kenneth R. Hess, Carlos H. Barcenas, Banu Arun, Elizabeth A. Mittendorf, Marion E. Scoggins
Publikováno v:
J Clin Oncol
PURPOSE Talazoparib has demonstrated efficacy in patients with BRCA-positive metastatic breast cancer. This study evaluated the pathologic response of talazoparib alone for 6 months in patients with a known germline BRCA pathogenic variant (g BRCA-po
Autor:
Gordon Broderick, Eileen H. Shinn, Bryan Fellman, Ainslee Johnson, Elizabeth Wieland, William Fraser Symmans, Stacy L. Moulder
Publikováno v:
JCO Clinical Cancer Informatics
PURPOSE Nearly 40% of patients with breast cancer discontinue their adjuvant oral endocrine treatment (ET). We measured discontinuation rates of ET at a comprehensive cancer center. We then used an iterative approach to model patterns of determinants
Publikováno v:
American Society of Clinical Oncology Educational Book. :65-77
Metastatic breast cancer continues to be a life-threatening diagnosis that impacts hundreds of thousands of patients around the world. Targeted therapies are usually associated with less toxicity compared with cytotoxic chemotherapies and often induc
Autor:
Robert R. Jenq, Lei Huo, Bora Lim, Alastair M. Thompson, Naoto T. Ueno, Gabriel N. Hortobagyi, Elizabeth Ravenberg, Rashmi Krishna Murthy, Banu Arun, Chia-Chi Chang, Elizabeth A. Mittendorf, Clinton Yam, Debu Tripathy, Jennifer K. Litton, Senthil Damodaran, Stacy L. Moulder, Nuhad K. Ibrahim, Vicente Valero, Nour Abuhadra, Jason B White
Publikováno v:
Journal of Clinical Oncology. 39:590-590
590 Background: The impact of gut microbiome on tumor biology, progression and response to immunotherapy has been shown across cancer types. However, there is little known about the impact of gut microbial composition on response to chemotherapy. We
Autor:
Debu Tripathy, Clinton Yam, Alastair M. Thompson, Senthil Damodaran, Beatriz E. Adrada, Lei Huo, Elizabeth A. Mittendorf, Rashmi Krishna Murthy, Sabitha Prabhakaran, William Fraser Symmans, Stacy L. Moulder, Sahil Seth, Jason B White, Ryan Sun, Rosalind P. Candelaria, Vicente Valero, Elizabeth Ravenberg, Gaiane M. Rauch, Alyson Clayborn, Jennifer K. Litton
Publikováno v:
Journal of Clinical Oncology. 39:592-592
592 Background: Neoadjuvant anti-PD-(L)1 therapy confers an improvement in pathological complete response (pCR) rate in unselected TNBC. However, given the potential for long-term morbidity from immune related adverse events (irAE), it is important t
Autor:
Gabriel N. Hortobagyi, Banu Arun, Rosalind P. Candelaria, Gaiane M. Rauch, Debu Tripathy, Jennifer K. Litton, Elizabeth A. Mittendorf, Senthil Damodaran, Elizabeth Ravenberg, Vicente Valero, Bora Lim, Lumarie Santiago, Naoto T. Ueno, Roland L. Bassett, Jason B White, Lei Huo, Alastair M. Thompson, Beatriz E. Adrada, Rashmi Krishna Murthy, Stacy L. Moulder
Publikováno v:
Journal of Clinical Oncology. 38:595-595
595 Background: 40-50% of pts with TNBC develop pathologic complete response (pCR) with adriamycin/cyclophosphamide (AC)àtaxane (T) NAT; thus, most pts treated in randomized trials (RCTs) adding experimental drugs (ED) to standard NAT do not benefit
Autor:
Naoto T. Ueno, Rashmi Krishna Murthy, Nuhad K. Ibrahim, William Fraser Symmans, Elizabeth Ravenberg, Elizabeth A. Mittendorf, Senthil Damodaran, Stacy L. Moulder, Bora Lim, Alastair M. Thompson, Nour Abuhadra, Lumarie Santiago, Gaiane M. Rauch, Lei Huo, Banu Arun, Ryan Sun, Rosalind P. Candelaria, Beatriz E. Adrada, Jason B White, Jennifer K. Litton
Publikováno v:
Journal of Clinical Oncology. 38:583-583
583 Background: Pathologic complete response is an excellent surrogate for disease-free survival (DFS) and overall survival (OS) in TNBC. High sTIL is associated with improved pCR rates in TNBC. Recent data suggest that high sTIL is also associated w
Autor:
Banu Arun, Bora Lim, Debu Tripathy, Senthil Damodaran, Jianhua Zhang, Elizabeth A. Mittendorf, Lumarie Santiago, Beatriz E. Adrada, Reva Basho, Jennifer K. Litton, Li Zhao, Elizabeth Ravenberg, Alastair M. Thompson, Jason B White, Lei Huo, Stacy L. Moulder, Clinton Yam, Vicente Valero
Publikováno v:
Journal of Clinical Oncology. 38:561-561
561 Background: Limited cell line and human data suggest that TNBCs characterized as mesenchymal and luminal androgen receptor (LAR) commonly have alterations in the PI3K pathway. More data is needed to better characterize the role of the PI3K pathwa
Autor:
Gaiane M. Rauch, Naoto T. Ueno, Jennifer K. Litton, Roland L. Bassett, Angelica M. Gutierrez Barrera, Stacy L. Moulder, Li Zhao, Debu Tripathy, Rosalind P. Candelaria, Vicente Valero, Banu Arun, Jason B White, Alastair M. Thompson, Rachel M. Layman, Elizabeth Ravenberg, Jianhua Zhang
Publikováno v:
Journal of Clinical Oncology. 38:1546-1546
1546 Background: Previous studies have related germline BRCA mutations to pathologic complete response (pCR) in TNBC cohorts. However, prospective data is lacking on the frequency of non- BRCA germline mutations and pCR in TNBC patients who received
Autor:
Jennifer K. Litton, Bora Lim, Rosalind P. Candelaria, Rachel M. Layman, Alastair M. Thompson, William Fraser Symmans, Debu Tripathy, Senthil Damodaran, Lei Huo, Rashmi Krishna Murthy, Vicente Valero, Jianjun Zhang, Naoto T. Ueno, Banu Arun, Gaiane M. Rauch, Qingqing Ding, Stacy L. Moulder, Li Zhao, Sahil Seth, Jason B White
Publikováno v:
Journal of Clinical Oncology. 38:517-517
517 Background: The luminal androgen receptor (LAR) subtype of TNBC has a low pathologic complete response (pCR) rate after NAT. We determined the pCR rate of the enzalutamide and paclitaxel (ZT) regimen for pts with anthracycline-insensitive AR+ TNB